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Background: Breast cancer is the most common cancer in women. Among the survivors, 
depression is one of the most common psychiatric comorbidities. This paper reports the point 
prevalence of major depressive disorder among breast cancer patients and the association 
between family support and major depressive disorder.
Methods: Clinical data were collected from a breast cancer clinic of a general hospital in central 
Taiwan. Participants included 300 patients who were older than 18 years and diagnosed with 
breast cancer. Among these individuals, we used Mini International Neuropsychiatric Interview 
(a structural diagnostic tool for psychiatric disorders) to ascertain if they had major depressive 
disorder. We also used the Family Adaptability, Partnership, Growth, Affection, and Resolve 
score to assess the family support.
Results: The point prevalence of major depressive disorder among breast cancer patients 
was 8.33%, and this was positively associated with insomnia, psychiatric family history, pain 
severity, and radiotherapy and negatively associated with menopause, cancer duration, hormone 
therapy, and family support. Family support (adjusted odds ratio =0.87, 95% CI: 0.78–0.98) 
was found to be an associated factor for major depressive disorder in breast cancer patients 
after controlling for potential risk factors.
Conclusion: Major depressive disorder is a common comorbidity among breast cancer patients. 
Family support is an important associated factor for these patients. Health care professionals 
should evaluate mood problems and family support while treating these patients.
Keywords: breast cancer, prevalence, depression, family support, risk factors, psychiatric 
disorders
Introduction
Breast cancer is the most common cancer in women. It is also one of the leading 
causes of cancer death worldwide.1 With early diagnosis and treatment, the 5-year 
survival rate of breast cancer is 89%.2 However, the peak incidence of breast cancer 
falls in middle age. The patients usually play an important role either in families or 
in societies at the time that the diagnosis of breast cancer is given.3 Thus, the impact 
of breast cancer is significant physically, mentally, and socially.
It has been reported that many breast cancer patients experience great stress dur-
ing the course of treatment. Fear, worry, anger, uncertainty for the future, and body 
image concern are common responses.4–6 Depression is one of the most common 
psychiatric diagnoses in breast cancer survivals. The prevalence of depression ranges 
from 5% to 40%, and most studies report rates between 10% and 25%.7,8 In addition, 
the side effects of long-term hormone therapy or chemotherapy, such as menopause, 
pain, and insomnia may also lead to depression.9,10 Depression can worsen the feel-
ing of discomfort and may result in poorer outcome.11–14 Persistent depression has 
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been found to be associated with poorer cognition, family 
function, treatment compliance, greater physical distress, 
and more use of tobacco or alcohol, which decreased the 
quality of life.15–17
Several risk factors for depression in breast cancer 
patients have been reported such as being single, divorced, 
sleep disturbance, past history of depression, pain, neu-
roticism, and stressful life events.18–24 The roles of smoking, 
alcohol drinking, or exercise still remain unclear. Family 
support and social support are both important protective 
factors for depressive patients in the general population.25 
Family members are also affected by the changes experienced 
by the patient and must adjust to new roles in the cancer 
journey.26,27 Maly et al indicated that breast cancer patients 
with higher family support had less depressive or anxiety 
symptoms.28 It has also been reported that mental support and 
empathy from the spouse were related to lower depressive 
symptoms among elderly breast cancer survivals.29 Another 
study focusing on younger breast cancer patients pointed to 
the importance of family support after the diagnosis of breast 
cancer.30 However, research into the relationship of family 
support and depression was limited in Asia.
The aim of our study was to investigate the point preva-
lence of depression and the comprehensive risk factors among 
depression and breast cancer. In contrast to previous studies, 
we used Mini International Neuropsychiatric Interview 
(MINI), a structural diagnostic tool, to diagnose depression 
instead of evaluating the symptoms of depression by rating 
scales only.
Methods
study design
This is a cross-sectional study that was carried out in a gen-
eral hospital between October 2011 and September 2012. 
The potential participants were all breast cancer patients 
who attended the general hospital for cancer routine treat-
ment. We initially included patients older than 18 years with 
first diagnosis of breast cancer. Those who could not sign 
informed consent, individuals with intellectual disability or 
dementia were not invited for participation. The medical 
information we collected included three parts: 1) medical 
records including cancer staging and treatments (eg, opera-
tion, radiation therapy, chemotherapy, hormone therapy, 
targeted therapy); 2) assessment of psychiatric diagnosis 
by MINI and family support by Family Adaptability, Part-
nership, Growth, Affection, and Resolve (APGAR) score; 
and 3) demographic data, marital status, duration of breast 
cancer, exercising, psychiatric history, sleep condition, sleep-
ing pill use, substance use, pain severity by visual analog 
scale (VAS), and psychiatric family history. The study was 
approved by the institutional review board of Taichung 
Veterans General Hospital.
assessment tools
MINI is a structural diagnostic interview tool that was 
developed by Sheehan for Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition psychiatric diagnosis.31 
The Chinese version of MINI was used in other research in 
Taiwan.32 In the present study, the section of major depressive 
disorder in MINI was administered by a trained researcher.
Smilkstein’s Family APGAR score was developed in 1978 
and consisted of five questions for quantifying the perception 
of family functionality.33 The assessment of the individual’s 
satisfaction with their family functioning is based on the 
five parameters: adaptability, partnership, growth, affec-
tion, and resolve. The response options were designed to 
describe frequency of feeling satisfied with each parameter 
on a 3-point scale ranging from 0 (hardly ever) to 2 (almost 
always) and higher score means higher family support and 
functionality.
The VAS of pain provides a simple technique for mea-
suring subjective pain and has been found to be a valid and 
reliable tool in a range of clinical and research applications.34 
It is a graphic tool with a 100 mm horizontal line with the left 
end marked as “no symptom” and the right end marked as 
“worst imaginable symptom.” The patient is asked to draw 
a vertical line to indicate the horizontal scale at a point that 
corresponds to the intensity of pain. The length from the left 
end to the vertical mark made by the patient is measured in 
millimeters.
statistical analysis
The χ2- and unpaired t-tests were used to evaluate percentage 
and mean differences between MINI responders and non-
responders in terms of basic demographic characteristics, 
medical information, and family support score. We also 
compared the prevalence of major depression in different 
subgroups. Pain severity, Family APGAR score, and the 
associated factors showed statistical significance between 
the two groups were included in further logistic regression 
analyses. Unadjusted and adjusted logistic regressions 
were further used to determine the significance of associa-
tion. A p-value of 0.05 was used to indicate statistical 
significance.
Results
We screened 465 potential breast cancer patients for eligi-
bility. A total of 451 eligible breast cancer patients were 
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invited to participate in this study and completed the basic 
assessment including demographic data, medical records, life 
style, and Family APGAR score. Furthermore, 300 patients 
agreed to have assessment of psychiatric diagnosis by MINI. 
The protocol for participant selection is shown in Figure 1. 
The overall response rate is 66.5% (300/451). In Table 1, 
there was no difference for the age distribution, marital status, 
occupation, cigarette smoking, alcohol drinking, exercising 
habit, cancer stage, pain severity, and family support score 
between MINI responders and non-responders. All of them 
were female patients, and the mean age of responders was 
48.16±9.07 years. Half (50.3%) of the responders had been 
diagnosed with breast cancer within the past year. The mean 
duration of cancer diagnosis was 2.0±2.7 years. More than 
90% were in stage I–III, and surgery was the most common 
treatment option (82.3%). Other treatments included radio-
therapy (58.7%), chemotherapy (71.7%), hormone therapy 
(70%), and target-drug therapy (22.7%). Twenty-five patients 
met the criteria for a current major depressive disorder by 
MINI, and the overall prevalence was 8.33%.
Data and comparisons of the prevalence of major depres-
sive disorder in different subgroups are shown in Table 2. 
Insomnia, taking sleeping pills, positive psychiatric family 
history, chronic pain in the previous 1-year period, shorter 
breast cancer duration (1 year), radiation therapy, and 
without hormone therapy were related to higher prevalence 
of major depressive disorder. However, treatment for opera-
tion, target-drug therapy, and different cancer stage did 
not show a difference in prevalence. In addition, we also 
compared the Family APGAR score and pain severity 
score between those with and without major depression. 
The result showed that those without major depres-
sion had better family support (p0.001) and higher 
pain severity score (p0.001).
Family APGAR score, pain severity score, and the factors 
that were statistically significant in Table 2 were included in 
the regression model. The associations as shown by unad-
justed and adjusted logistic regression analyses are shown 
in Table 3. In the unadjusted model, insomnia, pain severity, 
and undergoing radiation therapy were associated with higher 
risks for major depressive disorder. On the other hand, longer 
duration of breast cancer, menopause, hormone therapy, and 
higher family support were associated with lower risks for 
major depressive disorder. In the final adjusted model, it was 
found that pain severity and undergoing radiotherapy were 
associated with higher risks for major depressive disorder. 
Higher family support and hormone therapy were associated 
with lower risks for major depressive disorder.
Discussion
In our study, the prevalence of major depressive disorder 
among breast cancer patients was 8.33%. This was related 
to pain severity, radiotherapy, hormone therapy, and family 
support. The results also showed that family support was an 
associated factor for major depressive disorder among breast 
cancer patients.
A meta-analysis by Zainal et al included 10,826 breast 
cancer patients from 32 research studies and found that the 
incidence of depressive disorder varied from 1% to 56%.35 
The median prevalence differed when using different diag-
nostic tools: 22% (13% to 56%) with Center of Epidemiologic 
Studies Depression, 22% (17% to 48%) with Beck Depres-
sion Index, and 10% (1% to 22%) with the Hospital Anxiety 
Depression Scale. In five other studies that used a structural 
diagnostic interview tool (Structural Clinical Interview for 
Diagnostic Statistical Manual), the mean prevalence was 
16.25% (9% to 25%).35 The prevalence of major depressive 
disorder in our study (8.33%) was lower than that in the stud-
ies mentioned above. In previous studies, the prevalence of 
depression has been found to be lower in Asia than in Western 
countries.36,37 Andrade et al studied the prevalence of major 
depressive episode in ten countries and reported that it was 
lower in Turkey and Japan compared to other countries in 
Europe or America.36 In another epidemiological study in 
Taiwan by Hwu et al, lower prevalence of major depressive 
([FOXGHGSDWLHQWVZKRPHWWKHH[FOXVLRQFULWHULD&RXOGQRWVLJQLQIRUPHGFRQVHQW:LWKLQWHOOHFWXDOGLVDELOLW\'HPHQWLD
$WRWDORISRWHQWLDOEUHDVWFDQFHUSDWLHQWVZHUHVFUHHQHGIRUHOLJLELOLW\
EUHDVWFDQFHUSDWLHQWVZHUHHOLJLEOHDQGKDYHEDVLFDVVHVVPHQWLQFOXGLQJGHPRJUDSKLFGDWDPHGLFDOLQIRUPDWLRQOLIHVW\OHDQG)DPLO\$3*$5VFDOH
EUHDVWFDQFHUSDWLHQWVUHIXVHGWRKDYHDVVHVVPHQWRISV\FKLDWULFGLDJQRVLVE\0,1,
$WRWDORIEUHDVWFDQFHUSDWLHQWVDJUHHGWRKDYHDVVHVVPHQWRISV\FKLDWULFGLDJQRVLVE\0,1,
Figure 1 Flowchart for participant selection.
Abbreviations: aPgar, adaptability, Partnership, growth, affection, and resolve; 
MiNi, Mini international Neuropsychiatric interview.
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disorder was reported in Taiwan than in the United States 
or Korea.37 A possible explanation might be that this reflects 
cultural variance and/or other ethnic differences. In addition, 
different study designs, cancer stages, and illness duration 
may lead to different prevalence rates.
With regard to the association between marital status and 
depression, findings tend to be inconsistent.35 Some studies 
showed that being single or divorced was more likely to be 
associated with depressive disorder.18,19 However, Pumo 
et al reported that married breast cancer patients had higher 
prevalence of depression.38 In our study, marital status had 
no significant relationship with major depressive disorder 
in final logistic regression analysis. It is possible that the 
number of depressed patients was too small to show any 
statistical difference.
In terms of the association between different treatment 
interventions and depression, some studies found that depres-
sion was more likely in patients undergoing chemotherapy18,39 
or radiation therapy.40–42 Another study indicated that those 
who had received prior chemotherapy were more likely to be 
depressed after radiation therapy but that radiation therapy 
alone did not increase the depressive symptoms.43 Our study 
showed that patients who received radiation therapy had 
significantly higher risks for depression. Radiotherapy is pre-
dominantly provided in breast cancer with poorer prognosis, 
and this possibly explains part of the association with depres-
sion. On the other hand, hormone treatment provided for 
hormone receptor-positive tumors are generally associated 
with better prognosis than hormone receptor-negative tumors. 
Thus, the incidence of depression is lower. Moreover, we did 
not consider the effects of combined treatment regimens, and 
the tolerability of chemotherapy and radiation therapy varied 
in different ethnic groups. Further prospective, longitudinal 
studies are needed to confirm the relationship of different 
treatment and depression.
Family support is an important factor in breast cancer 
patients, and our results showed that higher family support 
was associated with lower risk for depression. A prospective 
study following the patients for 23 years also reported that 
higher family support was related to lower levels of depres-
sion at baseline and quicker improvement of depression.25 
Support from the spouse is especially important. A previous 
Table 1 Baseline characteristics of breast cancer patients between MiNi responders and non-responders
Characteristics MINI responders 
(N=300)*
(%) Non-responders 
(n=151)
(%) p-value
age (mean sD) 48.16 9.07 48.85 7.87 0.43
18–40 years 63 (21.0) 22 (14.5) 0.24
41–54 years 171 (57.0) 91 (60.3)
55 years 66 (22.0) 38 (25.2)
Marriage
Yes 225 (75.3) 111 (74.0) 0.86
No 74 (24.7) 39 (26.0)
Occupation
Yes 125 (41.8) 70 (46.7) 0.38
No 174 (58.2) 80 (53.3)
cigarette smoking
Yes 29 (9.7) 9 (6.0) 0.24
No 270 (90.3) 142 (94.0)
alcohol drinking
Yes 101 (33.9) 51 (33.8) 1.00
No 197 (66.1) 100 (66.2)
regular exercise
Yes 172 (57.5) 80 (53.0) 0.41
No 127 (42.5) 71 (47.0)
insomnia
Yes 119 (39.8) 65 (43.0) 0.58
No 180 (60.2) 86 (57.0)
stage
i–iii 249 (96.5) 122 (97.6) 0.79
iV 9 (3.5) 3 (2.4)
Pain severity score (sD) 1.50 2.22 1.73 2.35 0.33
Family aPgar score (sD) 9.93 3.87 9.95 3.85 0.96
Note: *Missing data excluded.
Abbreviations: sD, standard deviation; MiNi, Mini international Neuropsychiatric interview; aPgar, adaptability, Partnership, growth, affection, and resolve.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
73
.1
21
.4
2 
on
 2
7-
O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2393
Depression in breast cancer patients
study reported that greater perceived support from the spouse 
was associated with lower levels of depression.29 Another 
study among breast cancer patients aged 55 years revealed 
that support from adult children was also related to less 
anxiety and depression.28 Northouse et al found that family 
support had a positive impact on quality of life for both the 
patients and their families.44 However, similar studies on fam-
ily support among breast cancer patients have been lacking in 
the Chinese population. Our study supported those previous 
findings that family support is also important for breast cancer 
patients in the Taiwanese and that family support helps to 
protect them from mood problems. For health professionals, 
it is important to understand family interactions during the 
course of the illness and to provide information about how to 
improve and maintain enough family support and functional-
ity. In addition, patients with depression might tend to report 
feeling less supported by their family. However, our study is 
a cross-sectional study design, and further prospective cohort 
study is needed to explore the causal relation.
Pain, anxiety, and depression have been found to be 
inter-correlated in breast cancer patients.45 We found that 
pain severity is associated with higher prevalence of depres-
sion. More than 80% of our participants underwent surgery. 
It has been reported that postoperative pain plays a role in 
Table 2 Prevalence of major depression based on risk factors in breast cancer patients (N=300)
Variables Group Major depression/ 
total number
Prevalence (%) 95% CI (%) p-value
Total patients 25/300 8.33 5.21–11.46
Basic characteristics
age 18–40 years 8/63 12.7 4.48–20.9 0.343
41–54 years 13/171 7.60 3.63–11.6
55 years 4/66 6.06 0.31–11.8
Marriage No 6/74 8.11 1.89–14.3 0.928
Yes 19/225 8.44 4.81–12.1
cigarette smoking No 22/270 8.15 4.88–11.4 0.793
Yes 3/29 10.3 0.0–21.4
alcohol drinking No 18/197 9.14 5.11–13.2 0.515
Yes 7/101 6.93 1.98–11.9
regular exercise Yes 11/172 6.40 2.74–10.1 0.153
No 14/127 11.0 5.58–16.5
Psychosocial factors
insomnia Yes 16/119 13.5 7.32–19.6 0.010
No 9/180 5.00 1.81–8.18
Taking sleeping pills Yes 8/47 17.0 6.28–27.8 0.019
No 17/252 6.75 3.65–9.84
Psychiatric family history Yes 6/27 22.2 6.54–37.9 0.006
No 19/254 7.48 4.25–10.7
chronic pain within one year Yes 14/84 16.7 8.70–24.6 0.001
No 11/215 5.12 2.17–8.06
cancer related factors
Menopause Yes 10/180 5.60 2.21–8.90 0.031
No 15/119 12.6 6.64–18.6
Duration of breast cancer #1 year 18/150 12.0 6.80–17.2 0.012
1 year 6/148 4.05 0.88–7.23
stage of cancer i–iii 20/249 3.4 1.15–5.65 0.540
iV 1/9 4.8 -9.17–18.8
Treatments
Operation Yes 21/247 8.50 5.02–12.0 0.819
No 4/53 7.55 0.44–14.7
radiation therapy Yes 20/176 11.36 6.67–16.1 0.024
No 5/124 4.03 0.57–7.49
hormone therapy Yes 13/210 6.19 2.93–9.45 0.040
No 12/90 13.33 6.31–20.4
chemotherapy Yes 20/215 9.30 5.42–13.2 0.334
No 5/85 5.88 0.88–10.9
Target-drug therapy Yes 8/68 11.7 4.11–19.4 0.244
No 17/232 7.33 3.97–10.7
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the development of chronic pain and depression.46 However, 
pain relief after cancer is sometimes suboptimal.47 Thus, in 
order to reduce the prevalence of depression in breast cancer 
patients, more aggressive pain control strategy is needed 
especially for those who underwent surgery.
Broeckel et al reported that longer periods after cancer 
diagnosis and chemotherapy completion were positively 
related to greater depressive symptoms.19 However, Khan 
et al found that recent diagnosis was associated with more 
severe depressive symptoms48 and that depression decreased 
with longer survival time.49 Our findings were consistent 
with those of the latter study. Cancer diagnosis within 
1 year was associated with depression. Mullan in 1985 
described the different stages in cancer journey.50 In the 
earlier stage, cancer patients underwent aggressive treat-
ments, experienced high levels of emotional stress, and fear 
of potential death, and therefore depression is more likely 
possible at that time. In the later stage, it is described as a 
permanent survival phase which carries less stress in the 
fear of recurrence and that less depression is noted during 
that phase.
Limitations
There are still a number of limitations in our study. First, this 
is a cross-sectional study and thus cannot indicate the causal 
relationship of risk factors and depression. It needs further 
prospective cohort study to provide evidence of causal links. 
Second, the sample size and the number of depressive patients 
are small. It might be difficult to show the significance in 
statistical analyses. Furthermore, the response is rather low 
(66.5%), and this might bias the estimated point prevalence 
of depression as well as the analyses of factors associated 
with depression. Third, we used only the section of major 
depressive disorder in MINI and did not rule out other psychi-
atric disorders such as schizophrenia or delusional disorder 
comorbidities with depression. Last, the study was carried 
out in a single general hospital; hence, generalization of our 
results to other hospital settings should be with caution.
Conclusion
The prevalence of major depressive disorder was 8.33% 
in breast cancer patients. This was associated with pain 
severity, radiation therapy, hormone therapy, and family 
support. In clinical practice, physicians should pay careful 
attention to those breast cancer patients with risk factors 
for depression. Timely intervention is needed for high-risk 
patients to reduce the impact of depression in breast cancer. 
In the future, further study can address on the possibility of 
reducing the depressive symptoms if enhancing the perceived 
family support.
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